Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection

Journal of Viral Hepatitis
I MederackeHep-Net/International Delta Hepatitis Study Group

Abstract

Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNα). The aim of this analysis was to assess the renal function during combination therapy with peginterferon alfa-2a (PegIFNα-2a) plus ADV vs either drug alone in patients with hepatitis B/D co-infection. We performed a retrospective analysis of renal function data of patients treated in the Hep-Net/International Delta Hepatitis Intervention Trial 1(HIDIT-1-trial), a European multicenter study to investigate the efficacy of 48 weeks of therapy with PegIFNα-2a+ADV vs either drug alone in 90 patients with chronic hepatitis B/D co-infection. Glomerular filtration rates (GFR) were calculated by Cockcroft-Gault (CG), abbreviated Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. After 48 weeks of therapy GFR values were significantly lower in patients receiving adefovir-containing treatment vs PegIFNα-2a alone [mean difference 16.1 mL/min (CG) and 10.2 mL/...Continue Reading

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
May 1, 1987·The Journal of Infectious Diseases·G FattovichG Realdi
Sep 23, 2003·Drugs·Toni Dando, Greg Plosker
Jan 11, 2005·Lancet·Harry L A JanssenUNKNOWN Rotterdam Foundation for Liver Research
Jul 1, 2005·The New England Journal of Medicine·George K K LauUNKNOWN Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group
Jun 9, 2006·The New England Journal of Medicine·Lesley A StevensAndrew S Levey
Aug 31, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Karsten WursthornJoerg Petersen
Mar 3, 2007·Clinical Chemistry·Andrew S LeveyUNKNOWN Chronic Kidney Disease Epidemiology Collaboration
Dec 5, 2008·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver
Apr 2, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Maurizia Rossana BrunettoPatrick Marcellin
Apr 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Robert J Fontana
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jun 12, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Nghi B HaMindie H Nguyen
Aug 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F Lok, Brian J McMahon
Jan 7, 2010·Nature Reviews. Gastroenterology & Hepatology·Heiner Wedemeyer, Michael P Manns
May 13, 2010·Current Hepatitis Reports·Tak Mao Chan
Aug 21, 2010·Journal of Viral Hepatitis·C YurdaydınA M Bozdayi
Oct 12, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Karsten WursthornNikolai V Naoumov
Jan 28, 2011·The New England Journal of Medicine·Heiner WedemeyerUNKNOWN HIDIT Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Robert J Fontana
Annals of Internal Medicine
Andrew S LeveyCKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
© 2021 Meta ULC. All rights reserved